| scholarly article | Q13442814 |
| P50 | author | Stepan Gambaryan | Q40206073 |
| Athanasios Papakyriakou | Q42710085 | ||
| P2093 | author name string | E Martin | |
| G A Spyroulias | |||
| I G Sharina | |||
| N Rukoyatkina | |||
| M Sobolevsky | |||
| P2860 | cites work | Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk | Q24630394 |
| RNA splicing in regulation of nitric oxide receptor soluble guanylyl cyclase | Q27001569 | ||
| The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands | Q27136827 | ||
| Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation | Q39845753 | ||
| Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation | Q39847509 | ||
| Clinical pharmacokinetics of fibric acid derivatives (fibrates). | Q41726692 | ||
| Dysfunctional nitric oxide signalling increases risk of myocardial infarction | Q42708482 | ||
| Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase | Q44626758 | ||
| Synthesis and evaluation of bifunctional sGC regulators: optimization of a connecting linker. | Q46190962 | ||
| A functional heme-binding site of soluble guanylyl cyclase requires intact N-termini of alpha 1 and beta 1 subunits. | Q53005214 | ||
| Low angle light scattering analysis: a novel quantitative method for functional characterization of human and murine platelet receptors | Q63407984 | ||
| General principles of assays for adenylate cyclase and guanylate cyclase activity | Q70057105 | ||
| Aging and chronic hypertension decrease expression of rat aortic soluble guanylyl cyclase | Q73371570 | ||
| Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure | Q84553919 | ||
| NO and CO differentially activate soluble guanylyl cyclase via a heme pivot-bend mechanism | Q27641107 | ||
| Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase | Q27661554 | ||
| The Amber biomolecular simulation programs | Q27860745 | ||
| Modeller: generation and refinement of homology-based protein structure models | Q28236254 | ||
| Mechanism of action of fibrates on lipid and lipoprotein metabolism | Q28288187 | ||
| Genome-wide association study in Han Chinese identifies four new susceptibility loci for coronary artery disease | Q29416988 | ||
| A semiempirical free energy force field with charge-based desolvation | Q29614316 | ||
| Inflammation and atherosclerosis | Q29615203 | ||
| Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group | Q29619877 | ||
| Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial | Q30080004 | ||
| The Concise Guide to PHARMACOLOGY 2013/14: nuclear hormone receptors | Q30486738 | ||
| The Concise Guide to PHARMACOLOGY 2013/14: enzymes. | Q30486745 | ||
| Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats | Q33178899 | ||
| Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. | Q33576435 | ||
| Effects of combination lipid therapy in type 2 diabetes mellitus | Q33889260 | ||
| Thrombin and collagen induce a feedback inhibitory signaling pathway in platelets involving dissociation of the catalytic subunit of protein kinase A from an NFkappaB-IkappaB complex | Q33897766 | ||
| YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components | Q33948966 | ||
| Molecular insights and therapeutic targets for diabetic endothelial dysfunction | Q34022332 | ||
| Animal research: reporting in vivo experiments: the ARRIVE guidelines | Q34116755 | ||
| Bezafibrate in men with lower extremity arterial disease: randomised controlled trial | Q34270340 | ||
| Alternative splicing impairs soluble guanylyl cyclase function in aortic aneurysm | Q34627792 | ||
| Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease | Q34687253 | ||
| NO-independent, haem-dependent soluble guanylate cyclase stimulators | Q34906036 | ||
| A constitutively activated mutant of human soluble guanylyl cyclase (sGC): implication for the mechanism of sGC activation | Q35234315 | ||
| Cobinamides are novel coactivators of nitric oxide receptor that target soluble guanylyl cyclase catalytic domain | Q35776824 | ||
| Pleiotropic effects of fibrates | Q36232396 | ||
| Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism | Q36411159 | ||
| Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development | Q36648534 | ||
| Alpha1 soluble guanylyl cyclase (sGC) splice forms as potential regulators of human sGC activity | Q36678534 | ||
| NO- and haem-independent soluble guanylate cyclase activators | Q37352787 | ||
| Loss of α1β1 soluble guanylate cyclase, the major nitric oxide receptor, leads to moyamoya and achalasia | Q37634112 | ||
| Endothelial function | Q37970041 | ||
| Novel vasodilators in heart failure | Q38072635 | ||
| Soluble guanylate cyclase stimulators in pulmonary hypertension | Q38149032 | ||
| Interactions of warfarin with drugs and food | Q38571033 | ||
| Guidelines for reporting experiments involving animals: the ARRIVE guidelines | Q39512979 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | gemfibrozil | Q384295 |
| P304 | page(s) | 2316-2329 | |
| P577 | publication date | 2015-02-10 | |
| P1433 | published in | British Journal of Pharmacology | Q919631 |
| P1476 | title | The fibrate gemfibrozil is a NO- and haem-independent activator of soluble guanylyl cyclase: in vitro studies | |
| P478 | volume | 172 |
| Q39200522 | Antiplatelet activity of drugs used in hypertension, dyslipidemia and diabetes: Additional benefit in cardiovascular diseases prevention. |
| Q100635461 | Homogeneous single-label cGMP detection platform for the functional study of nitric oxide-sensitive (soluble) guanylyl cyclases and cGMP-specific phosphodiesterases |
| Q39024203 | Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure |
| Q47133234 | Pharmacological preconditioning with gemfibrozil preserves cardiac function after heart transplantation |
| Q88171942 | Redox regulation of soluble guanylyl cyclase |
| Q38836199 | Targeting vascular (endothelial) dysfunction. |
| Q39185669 | The Positive Regulation of eNOS Signaling by PPAR Agonists in Cardiovascular Diseases. |
Search more.